Search clinical trials for: Evolocumab

Total 134 results

Hospital General Universitario Gregorio Marañon

Completed

Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia

Hypercholesterolemia

Spain
First Affiliated Hospital of Fujian Medical University

Recruiting

PCSK9 Inhibitor Treatment for Patients With SPG5

Hereditary Spastic Paraplegia Type 5

China
Amgen

Completed

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Rigshospitalet, Denmark

Withdrawn

Vascular Inflammation and Cholesterol Lowering Therapy

Lipid Lowering, Vascular Inflammation

Denmark
First Affiliated Hospital Xi'an Jiaotong University

Completed

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

Coronary Disease
Amgen

Completed

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia (RAMAN)

Homozygous Familial Hypercholesterolemia HoFH

India
Amgen

Terminated

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
UMC Utrecht
Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Unknown

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia (EVOLVE-FD)

Hyperlipoproteinemia Type III | Familial Dysbetalipoproteinemia
University Hospital, Grenoble

Recruiting

Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography (MICROPROTECT)

Atherosclerotic Cardiovascular Disease

France
Amgen
Organization of Teratology Information Specialists (OTIS) Research Center...

Terminated

Evolocumab Pregnancy Exposure Registry

Hypercholesterolemia; ASCVD; Pregnancy
Amgen

Completed

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
LIB Therapeutics LLC

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Homozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey, India
University Hospital Inselspital, Berne
Amgen; University of Bern

Completed

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) (EVOPACS)

Acute Coronary Syndrome

Switzerland
Second Xiangya Hospital of Central South University

Not yet recruiting

PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population

Acute Coronary Syndrome
Radboud University Medical Center
Amgen

Recruiting

Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody (FITTER)

Coronary Artery Disease | Atherosclerosis of Coronary Artery

Netherlands
LIB Therapeutics LLC

Completed

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (LIBerate-H2H)

Cardiovascular Diseases | Hypercholesterolemia

United States
Zibo Central Hospital

Recruiting

Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy

Adverse Effect of Cardiovascular Medications (Diagnosis)

China
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
University of Campinas, Brazil

Completed

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial (EXCEED-BHS3)

Diabetes Mellitus, Type 2 | Dyslipidemia Associated With Type II Diabetes Mellitus | Hypertension Arterial

Brazil
Annapoorna Kini

Completed

Effect of Evolocumab on Coronary Plaque Characteristics (YELLOW III)

Coronary Artery Disease

United States
Imperial College Healthcare NHS Trust
Imperial College London

Active, not recruiting

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) (EVOCAR-1)

Carotid Artery Stenosis

United Kingdom
University of Erlangen-Nürnberg Medical School

Completed

Effect of Evolocumab on Vascular Function (EVO)

Atherosclerotic Cardiovascular Disease

Germany
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Esperion Therapeutics, Inc.

Completed

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Hypercholesterolemia

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Spain, Finland, Sweden, Canada
Wuhan Union Hospital, China

Recruiting

High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study

Cerebral Atherosclerosis

China
Icahn School of Medicine at Mount Sinai

Completed

Rosuvastatin and Evolocumab for Coronary Artery Disease (Yellow V)

Coronary Artery Disease

United States
Hamid Al-Essa Organ Transplant Center

Completed

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Kideny Transplant Recipients With High Cardiovascular Risk Score

Kuwait
Beijing Anzhen Hospital

Unknown

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD) (FORWARD)

Dyslipidemia | High Risk Coronary Artery Disease

China
Amgen
TIMI Study Group

Completed

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy (LAPLACE)

Hyperlipidemia

United States, Canada, Denmark, Czechia, Hungary
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Canada
Canadian Medical and Surgical Knowledge Translation...
Amgen

Recruiting

A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy (SLICE-CEA)

Carotid Artery Stenosis | Asymptomatic Carotid Artery Stenosis

Canada
Federico II University

Recruiting

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

Hypercholesterolemia, Familial

Italy
Foundation IRCCS San Matteo Hospital
Fondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaborators

Withdrawn

Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction (ExOTIC)

ST-elevation Myocardial Infarction

Italy
Amgen

Completed

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Primary Hyperlipidemia and Mixed Dyslipidemia

Australia
Tianjin Chest Hospital

Recruiting

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome (EMSIACS)

Acute Coronary Syndrome | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

China
University of California, Los Angeles
Amgen

Terminated

Reducing Intracranial atheroSclErosis With Repatha (RISER)

Ischemic Stroke

United States
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4 (GAUSS-4)

Hypercholesterolemia

Japan
Amgen

Terminated

Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Dyslipidemia

Belgium, Denmark, Germany, Sweden, France, Italy, Portugal
Beijing Luhe Hospital

Recruiting

Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

STEMI

China
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Hamad Medical Corporation

Not yet recruiting

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

Dyslipidemias | STEMI
ECRI bv
GE Healthcare; Amgen; HeartFlow, Inc.

Withdrawn

Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion (MARKOV)

Coronary Artery Disease
Policlinico Casilino ASL RMB
IRCCS San Raffaele

Unknown

Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

Hypercholesterolemia | CKD Stage 5 | Chronic Kidney Disease Requiring Chronic Dialysis

Italy
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more
Federico II University

Recruiting

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (AT-TARGET-IT)

Hypercholesterolemia

Italy
Assistance Publique - Hôpitaux de Paris
Amgen; Action Research Group

Recruiting

Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI (AMUNDSEN)

NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction

France
Amgen

Completed

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Heterozygous Familial Hypercholesterolemia

United States, Canada, Italy, Norway, Belgium, Turkey, Australia, New Zealand, Austria, Czechia, South Africa, Poland, Spain, Switzerland, Netherlands, Taiwan, Finland, Brazil, Portugal, Slovenia, Russian Federation, Hungary, United... and more
Amgen

Completed

A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects (AMG145)

Hypercholesterolemia and High Risk for Cardiovascular Events

Japan
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway

Search clinical trials for: Evolocumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations